Tc 99m tilmanocept

Drug Profile

Tc 99m tilmanocept

Alternative Names: Lymphoseek; NEO3-09; Tc 99m-diethylenetriamine pentaacetic acid mannosyl dextran; Tc 99m-DTPA-mannosyl dextran; Technetium Tc 99m tilmanocept; Tilmanocept

Latest Information Update: 23 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator University of California, San Diego
  • Developer Maimonides Medical Center; National Cancer Institute (USA); Navidea Biopharmaceuticals; Norgine; University of California, San Diego
  • Class Imaging agents; Radiopharmaceutical diagnostics; Radiopharmaceuticals; Small molecules
  • Mechanism of Action Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Head and neck cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Breast cancer; Head and neck cancer; Malignant melanoma; Solid tumours; Squamous cell cancer
  • Phase II Cervical cancer; Kaposi's sarcoma
  • Phase I Cardiovascular disorders; Endometrial cancer; Liver metastases; Rheumatoid arthritis
  • Clinical Phase Unknown Colorectal cancer

Most Recent Events

  • 09 Aug 2017 Navidea Biopharmaceuticals plans a phase I trial for Rheumatoid arthritis (Diagnosis) (NCT03241446)
  • 20 Jun 2017 Navidea Biopharmaceuticals licenses Tc 99m tilmanocept to Sayre Therapeutics in India
  • 12 Jun 2017 Launched for Breast cancer (Diagnosis) in United Kingdom, Netherlands, Denmark (Intradermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top